A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Sponsor: Eli Lilly and Company
This PHASE1 trial investigates Carcinoma, Non-small Cell Lung and is currently completed. Eli Lilly and Company leads this study, which shows 17 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1
▶ Show 12 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Dec 2019 — Oct 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .